Figure 7. The anti-tumour activity of an autophagy inhibitor in combination with topotecan treatment in a HCT116 human colon cancer xenograft model.

Athymic nude mice were injected subcutaneously with 4×10⁶ HCT116 p53^+/+ or HCT116 p53^−/− cancer cells. Six mice were assigned into each of the treatment groups. The tumours were allowed to grow for approximately 5 d to produce an average tumour volume of 40 mm³ prior to drug treatment. Topotecan was intraperitoneally administered once every 4 d (2 mg/kg), and CQ was intraperitoneally administered every day (10 mg/kg). The tumour growth was measured every 4 days according to the method described in the “Materials and Methods” section. Results are presented as means ± s.d. (n  =  6). *P<0.05, Student’s t test.